Compare DUOL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOL | AXSM |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.0B |
| IPO Year | 2021 | 2015 |
| Metric | DUOL | AXSM |
|---|---|---|
| Price | $118.94 | $181.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $270.00 | $197.95 |
| AVG Volume (30 Days) | ★ 2.6M | 693.8K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 338.81 | N/A |
| EPS | ★ 8.04 | N/A |
| Revenue | ★ $964,271,000.00 | $561,263,000.00 |
| Revenue This Year | $40.64 | $67.77 |
| Revenue Next Year | $22.43 | $58.56 |
| P/E Ratio | $14.86 | ★ N/A |
| Revenue Growth | 39.86 | ★ 65.83 |
| 52 Week Low | $112.41 | $86.99 |
| 52 Week High | $544.93 | $191.50 |
| Indicator | DUOL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 20.55 | 56.86 |
| Support Level | $112.41 | $180.02 |
| Resistance Level | $125.00 | $188.45 |
| Average True Range (ATR) | 7.39 | 5.33 |
| MACD | -2.31 | -1.44 |
| Stochastic Oscillator | 8.02 | 44.12 |
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.